Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients

Biomarkers

Volumn 21, Issue 1, 2016, Pages 80-90

  Liu, Fei ^a   Gu, Lina ^a   Cao, Yu ^a   Fan, Xiaojie ^a   Zhang, Fengjuan ^a   Sang, Meixiang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Enhancer of zeste homology 2; esophageal squamous cell carcinoma; histone 3 on lysine 27; prognosis

Indexed keywords

HISTONE H3; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HISTONE; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION; ESOPHAGUS TUMOR; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METHYLATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN PROCESSING; SECONDARY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHYLATION; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84949198662     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1118537     Document Type: Article

References (32)

1. Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. (2014). Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One 9: e108265
2. Besharat S, Jabbari A, Semnani S, et al. (2008). Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol 14: 3725-8
3. Bryant RJ, Cross NA, Eaton CL, et al. (2007). EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547-56
4. Cai MY, Hou JH, Rao HL, et al. (2011a). High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 17: 12-20
5. Cai MY, Tong ZT, Zhu W, et al. (2011b). H3K27me3 protein is a promising predictive biomarker of patients survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med 17: 1137-45
6. Cao R, Wang L, Wang H, et al. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-43
7. Cardoso C, Mignon C, Hetet G, et al. (2000). The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 8: 174-80
8. Crea F. (2011). Biological significance of DNA methylation patterns in human progenitor cells. Epigenomics 3: 12-3
9. Diaz E, Machutta CA, Chen S, et al. (2012). Development and validation of reagents and assays for EZH2 peptide and nucleosome highthroughput screens. J Biomol Screen 17: 1279-92
10. Debeb BG, Gong Y, Atkinson RL, et al. (2014). EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33: 58
11. Eskander RN, Ji T, Huynh B, et al. (2013). Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23: 997-1005
12. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-98
13. Esteller M. (2008). Epigenetics in cancer. N Engl J Med 358: 1148-59
14. Gu H, Qiu W, Shi Y, et al. (2014). Variant alleles of VEGF and risk of esophageal cancer and lymph node metastasis. Biomarkers 19: 252-8
15. He LJ, Cai MY, Xu GL, et al. (2012). Prognostic significance of overexpression of EZH2 and H3K27me3 proteins in gastric cancer. Asian Pac J Cancer Prev 13: 3173-8
16. Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90
17. Li H, Xiao W, Ma J, et al. (2014). Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7: 7989-98
18. Lin CS, Chang SC, Wei YH, et al. (2009). Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 87: 1056-65
19. Ma R, Wei Y, Huang X, et al. (2013). Inhibition of GSK 3β activity is associated with excessive EZH2 expression and enhanced tumour invasion in nasopharyngeal carcinoma. PLoS One 8: e68614
20. Margueron R, Reinberg D. (2011). The Polycomb complex PRC2 and its mark in life. Nature 469: 343-9
21. McCabe MT, Ott HM, Ganji G, et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-12
22. Ngollo M, Lebert A, Dagdemir A, et al. (2014). The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer 14: 994
23. Piunti A, Pasini D. (2011). Epigenetic factors in cancer development: polycomb group proteins. Future Oncol 7: 57-75
24. Schlesinger Y, Straussman R, Keshet I, et al. (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-6
25. Schwartz YB, Pirrotta V. (2007). Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 8: 9-22
26. Strahl BD, Allis CD. (2000). The language of covalent histone modifications. Nature 403: 41-5
27. Studo T, Utsunomiya T, Mimori K, et al. (2005). Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754-8
28. Tan J, Yang XJ, Zhuang L, et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-63
29. Tonini T, DAndrilli G, Fucito A, et al. (2008). Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 214: 295-300
30. Viré E, Brenner C, Deplus R, et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-4
31. Widschwendter M, Fiegl H, Egle D, et al. (2007). Epigenetic stem cell signature in cancer. Nat Genet 39: 157-8
32. Yoo KH, Hennighausen L. (2012). EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8: 59-65